Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with breast cancer for the first time by a doctor.
- People who have finished chemotherapy (either as a main treatment or after surgery) within the past 3 months, where the chemotherapy drugs used included paclitaxel, vinblastine, or platinum-based drugs.
- People whose doctor has determined that their nerve-related symptoms (such as tingling, numbness, or weakness) were caused by chemotherapy, and those symptoms are still present after chemotherapy has ended.
- People whose chemotherapy-related nerve symptoms have been rated as moderate or severe (grade 2 or higher) based on a standard medical assessment scale.
- People who are fully conscious and able to communicate in Mandarin or Taiwanese.
Who may not be able to join:
- People whose breast cancer is classified as "carcinoma in situ" (a very early, contained form of cancer).
- People with stage IV (the most advanced stage) breast cancer.
- People whose cancer has spread to other parts of the body (metastatic cancer).
- People currently taking the medication duloxetine for nerve-related symptoms.
- People currently receiving acupoint stimulation therapy (a treatment that targets specific points on the body).
- People who have an allergy to silicone patches.
- People who have a cardiac pacemaker (a device implanted in the chest to regulate heartbeat).
- People whose nerve symptoms are caused by diabetes rather than chemotherapy.
- People whose nerve symptoms are related to HIV/AIDS.
- People currently receiving treatment for a mental illness.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: WANG, PHD, National Taipei University of Nursing and Health Sciences
Phone: +886912631133
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity, FACT/GOG-NTX; Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity, FACT/GOG-NTX; Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity, FACT/GOG-NTX
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.